

# **GEMINI SL** Total Knee System with SPAR-K Instruments





#### FEMORAL ALIGNMENT GUIDE

Fast lock / unlock mechanism with colour code

Self-explaining /

### The GEMINI SPAR-K Instruments


meet the need of today's knee surgeons

#### The GEMINI SPAR-K Instruments

- are clear and easy to use
- are intuitive and efficient instruments.
- assure precise and reliable bone resections

## Efficient Precise Reliable





### SPAR-K Instruments for GEMINI SL Total Knee System

The instruments assure precise and reliable bone resections.

The GEMINI SPAR-K Instruments are designed to help the surgeon to consistently achieve optimal outcomes. They enable the surgeons to precisely control the implant position and fit for each patient.

The GEMINI SPAR-K Instruments allow a variety of surgical options such as:

- Femur first
- Tibia first
- Gap balancing



The colour coded actuators, the quick set/release functions and the single layer trays, allow for:

- A potential reduction of the learning curve
  - Reduced effort throughout the surgical process

for both surgeon and scrub-tech personal

#### Please feel free to visit our SPAR-K Instruments Website






748\_GEMINI SL SPAR-K\_Teaserflyer\_en\_2020-03\_003









A rating of 3A is given to implants that have demonstrated at least

**94,5% survival at 3 years** based on data meeting ODEP's criteria for the strongest data quality<sup>2</sup>.

The Mobile Bearing configuration of the **GEMINI SL** received this high quality rating for a knee implant awarded by the United Kingdom's Orthopaedic Data Evaluation Panel.

Latest ODEP ratings can be found at http://www.odep.org.uk

ODEP rating received in Autumn 2019

- <sup>1</sup> 10A: A minimum cohort of 500 knees at the start of the study with a minimum of ten years follow-up and an actual revision rate of less than 7%. All deaths, loss to follow-up, failures and indications for revisions are recorded. Minimum at risk at benchmark time: 51.
- <sup>2</sup> 3A: A minimum cohort of 150 knees at the start of the study with a minimum of ten years follow up and an actual revision rate of less than 5.5%. All deaths, loss to follow-up, failures and indications for revisions are recorded. Minimum at risk at benchmark time: 66.